



## **OPERATIONS ORDER**

### **Administration of Naloxone (NARCAN)**

#### **Purpose and Scope**

This order establishes guidelines and procedures regarding the administration of Naloxone (NARCAN). The objective of administering Naloxone is to reduce injuries and fatalities associated with opioid overdoses or fentanyl exposures.

Fentanyl-related substances are designed to be absorbed into the body by several means, including injection, oral ingestion, contact with mucous membranes, inhalation, and via transdermal transmission (through the skin). As such, accidental exposure of law enforcement officers is a real danger. Accidental exposure can occur under a number of circumstances, including during the execution of search or arrest warrants, probation searches, or the processing of evidence (e.g., drug proceeds, pill presses, scales or drug paraphernalia) that may be contaminated with these substances.

Due to the high potency of fentanyl and fentanyl-related substances, exposure to small quantities can cause serious negative health effects, respiratory depression, and even death.<sup>1</sup> Trainings, tactics, and Personal Protective Equipment (PPE) to include NARCAN can mitigate these effects.

#### **Affected Personnel**

Armed officers as well as Supervisors, Watch Commanders, and Managers overseeing armed officers.

#### **Authority**

Administrative Directive

#### **Effective Date**

September 15, 2020

#### **Definitions:**

***Naloxone Hydrochloride:*** A life-saving medication that works to reverse an opioid overdose while having little to no effect on an individual if opioids are not present in their system. Naloxone blocks opioid receptor sites, reversing the toxic effects of opioid overdose.

---

<sup>1</sup> The United States Department of Justice, Drug Enforcement Administration. (2017). *Fentanyl: Briefing Guide for First Responders*.

**NARCAN:** A brand name for naloxone.

**Opioids:** A class of drugs that include the illegal drug heroin, synthetic opioids (such as fentanyl), and pain relievers available by prescription such as oxycodone (Oxycontin), hydrocodone (Vicodin), codeine, morphine, methadone and others.

**Opioid Overdose:** The consumption of excessive quantities of opioids that result in physical illness including a condition of a decreased level of consciousness, respiratory depression, coma, or ceased respiratory or circulatory function. An overdose can be accidental or deliberate. Opioid overdose symptoms can include being non-responsive to touch or voice stimuli, constricted pupils, slow or no pulse, slow or irregular breathing, or fingernails and lips that appear blue or grey in color.

**SCEMSA:** Sacramento County Emergency Medical Services Agency. This agency is responsible for the medical oversight of the Emergency Medical Services (EMS) system in Sacramento County.

## **I. Training**

- A. It is the general policy of the Sacramento County Probation Department to require armed officers to be trained prior to administering NARCAN in the field.
- B. Armed officers shall receive initial NARCAN training that will include the following:
  - 1. An overview of Civil Code section 1714.22, which permits law enforcement's administration of NARCAN;
  - 2. Subject assessment for signs and symptoms of opioid overdose and self-assessment for signs of fentanyl exposure;
  - 3. Scene safety;
  - 4. Universal precautions to include use of Personal Protective Equipment;
  - 5. Use of NARCAN;
  - 6. How to seek medical attention; and
  - 7. Documentation required post NARCAN care.
- C. Armed Officers shall receive NARCAN update training every 2 years.

## **II. Deployment**

- A. The Probation Department's Professional Standards Division will distribute NARCAN nasal sprays kits to each armed officer.
- B. Officers will use their training and experience in deciding whether a subject is suffering from a suspected overdose of opioids, or whether they have been exposed to Fentanyl and are exhibiting signs of overdose symptoms.
- C. Upon administering NARCAN, officers shall contact the Dispatch Center as soon as possible to request response by emergency medical personnel and shall monitor the subject's vital signs (e.g., respiration, pulse) until Fire/EMS personnel arrive on scene.

- D. If the initial dose of NARCAN is ineffective, officers may consider administering a second dose only, and should continue to monitor vital signs if safe to do so.

### **III. Reporting Requirements**

- A. Upon administering NARCAN, notify the Supervisor and Watch Commander when safe to do.
- B. Complete the applicable report(s) (Crime, Informational, Event Report) and include a complete description of how and why NARCAN was used.
- C. Complete the mandatory SCESMA Law Enforcement Naloxone Utilization Report on the Sacramento County Health and Human Services website within 48 hours (**Attachment A**). A completed printout of the SCESMA report shall be attached to the Crime Report, Incident Report, or Event Report and the report shall document the form was completed. In addition, the reporting officer will email the Utilization Report to the Naloxone Program Coordinator.

### **IV. Storage, Maintenance, and Replacement**

- A. Storage
  - 1. NARCAN is a perishable medication and extreme temperatures may reduce the effectiveness of the medication.
  - 2. While on duty, Officers shall store the NARCAN nasal spray kits in the following primary locations:
    - a. Inside the officer's assigned locked locker;
    - b. Inside the safety kits located in the trunk of a county vehicle;
    - c. In the glove box of the county vehicle;
    - d. On the officer's person inside their tactical vests or pockets;
    - e. Inside the officer's go bag or backpack; or
    - f. Officers with home retention vehicles may secure the NARCAN in those vehicles.
  - 3. Off Duty: Officers shall store their NARCAN nasal spray kits in their secured lockers in their assigned Probation building at the end of their shift, or while they are off duty. Officers shall not store the NARCAN nasal spray kits in their personal vehicles or inside their county-issued Probation vehicles when not working.
  - 4. Additional NARCAN nasal spray kits shall be stored in a secured storage container at each Probation building and readily available to all officers in the event of an onsite exposure.
- B. Maintenance
  - 1. Each armed officer shall be responsible for the inspection of their assigned NARCAN nasal spray kits. The inspection should be done at the beginning of each shift to ensure the kits are serviceable and not expired.
  - 2. Missing, damaged, or expired Naloxone nasal sprays shall be immediately reported to a Supervisor and an Event Report shall be submitted.

C. Replacement

1. When the NARCAN nasal spray kit has been used, the officer should obtain a replacement kit as soon as reasonably possible by notifying the designated Watch Commander or Range Master.
2. Officers shall remove expired NARCAN nasal spray units from service and replace them with a new unit.

**Attachments**

- A. SCEMSA Law Enforcement Naloxone Utilization Report
- B. NARCAN Nasal Spray 4mg. (photo of medication)

**Amends/Replaces**

N/A - NEW

**Authorized By**



*Lee Seale, Chief Probation Officer*

**Date**

8/18/2020



ATTACHMENT A:

Form can be located at <https://dhs.saccounty.net/PRI/EMS/Pages/Forms.aspx>



## SCEMSA Law Enforcement Naloxone Utilization Report

This form shall be completed after use of Naloxone by Law Enforcement Personnel and submitted to SCEMSA within forty-eight (48) hours of utilization of Naloxone.

### Law Enforcement Agency Information

Agency Name: \*

Incident Date: \*

<input type="text"/>	/	<input type="text"/>	/	<input type="text"/>	
MM		DD		YYYY	

Event/Report Number: \*

Dispatch Time: \*

<input type="text"/>	:	<input type="text"/>	:	<input type="text"/>	AM	<input type="button" value="v"/>
HH		MM		SS	AM/PM	

On Scene Time:

<input type="text"/>	:	<input type="text"/>	:	<input type="text"/>	AM	<input type="button" value="v"/>
HH		MM		SS	AM/PM	

**Incident Location (including city): \***

**Patient Information**

Please complete this section with all information you were able to obtain.

**Patient Name:**

--	--

First                      Last

\*

Male                                       Female

**Age of Patient or Approximate Age: \***

**Date of Birth (if known):**

**Indication/Presenting Patient Condition: \***



**Naloxone Administration Details:**

**Time Naloxone Administered: \***

<input type="text"/>	:	<input type="text"/>	:	<input type="text"/>	AM	<input type="button" value="v"/>
HH		MM		SS	AM/PM	

**First Dose: \***

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**Additional Comments/Notes/Complications:**

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**Patient Response to Naloxone Administration: \***

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**Second Dose (if given):**

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**Time Repeat Dose Given:**

<input type="text"/>	:	<input type="text"/>	:	<input type="text"/>	AM	<input type="button" value="v"/>
HH		MM		SS	AM/PM	

**Patient Response to Naloxone Administration:**

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**Time Third Dose Given:**

<input type="text"/>	:	<input type="text"/>	:	<input type="text"/>	AM	<input type="button" value="v"/>
HH		MM		SS	AM/PM	

**Patient Response to Naloxone Administration:**

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**EMS Provider Assuming Patient Care: \***

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**If Other please indicate which provider/agency transported:**

<input type="text"/>	<input type="button" value="v"/>
----------------------	----------------------------------

**Treating Officer Name: \***

<input type="text"/>
----------------------

**Badge/Unit Number: \***

<input type="text"/>
----------------------

**Naloxone lot/serial number(s) or tracking number(s): \***

<input type="text"/>
----------------------

**Agencies Liaison(s) Email:**

<input type="text"/>
----------------------



ATTACHMENT B:



## Give Naloxone

For use in the nose only Rx Only  
NDC 69547-353-02

**NARCAN<sup>®</sup> (naloxone HCl)  
NASAL SPRAY 4 mg**

Each dose contains 4 mg naloxone HCl  
in 0.1 mL nasal spray  
1 spray per unit

Store at room temperature between  
59°F to 77°F (15°C to 25°C)  
Excursions permitted between  
39°F to 104°F (4°C to 40°C)  
Do not freeze. Protect from light.


Use for known or suspected opioid overdose  
in adults and children

**SEE ENCLOSED QUICK START GUIDE**

LOT 00000 & EXP MMM/YYYY

Distributed by Adapt Pharma, Inc. Radnor, PA 19087 USA  
A1004.01

**DO NOT TEST DEVICE BEFORE USE**



Remove NARCAN Nasal Spray from the box.

Peel back the tab with the circle to open the NARCAN Nasal Spray.